Présentation de l'entreprise
Chemed Corporation operates within the healthcare sector, specifically focusing on the medical care facilities industry by delivering comprehensive hospice and palliative care services to patients. This operational scope is executed through a distributed network comprising physicians, registered nurses, home health aides, social workers, clergy, and volunteers, with primary service delivery occurring across the United States. The company manages a substantial scale, evidenced by a market capitalization of $5.78 billion and annual revenues totaling $2.53 billion, while supporting an workforce of 15,811 employees. These financial dimensions indicate a significant market presence, positioning Chemed as a major entity capable of sustaining extensive operational networks and generating substantial cash flows relative to its peers in the specialized care facilities landscape.
Santé financière
The company's financial performance over the trailing twelve months reflects a revenue base of $2.53 billion, yielding a net income of $265.24 million and an EBITDA of $404.40 million. The substantial gap between the $2.53 billion in revenue and the $265.24 million in net income highlights a distinct cost structure where operating expenses, including the costs associated with a large employee base and clinical delivery, consume approximately 89.5% of gross revenue before interest and taxes. Operating free cash flow stands at $246.01 million, which provides the entity with significant financial flexibility to fund capital expenditures, manage working capital requirements, or potentially return capital to shareholders without compromising operational stability. The margin profile reveals a gross margin of 32.5%, an operating margin of 16.6%, and a profit margin of 10.5%, indicating that while the core service delivery retains a healthy gross spread, significant overheads are required to support the clinical and administrative infrastructure. Liquidity and solvency metrics show the company holds $74.52 million in cash against $143.76 million in debt, resulting in a debt-to-equity ratio of 14.68, which suggests a leveraged balance sheet typical of capital-intensive service providers. Short-term liquidity is assessed via a current ratio of 1.05, indicating that current assets are slightly higher than current liabilities, providing a comfortable but tight buffer for meeting immediate obligations. Return metrics demonstrate a return on equity of 25.3% and a return on assets of 13.4%, revealing that management is highly effective at leveraging shareholder capital and utilizing the company's asset base to generate superior returns relative to the industry average.
Évaluation de la valorisation
Valuation multiples for Chemed Corporation include a trailing twelve-month P/E ratio of 21.55 and a forward P/E of 14.85. The notable contraction between the trailing and forward P/E multiples implies that the market expects earnings growth to accelerate significantly in the future, as the forward metric suggests the stock is priced to grow at a rate that will substantially compress the earnings yield over the next fiscal year. The price-to-book ratio is calculated at 5.53, indicating that the market values the company's equity at more than five times its book value, which reflects a significant premium assigned to the intangible assets, brand strength, and stable cash flows inherent in the hospice care business. Alternative valuation metrics such as a price-to-sales ratio of 2.28 and an EV/EBITDA of 13.62 provide a broader perspective on value, suggesting that the company trades at a premium relative to its sales and earnings before interest, taxes, depreciation, and amortization compared to traditional manufacturing firms. Price action over the last year has oscillated between a 52-week high of $604.91 and a 52-week low of $365.21, with the current trading price situated within this historical range, reflecting recent market sentiment and volatility. The stock exhibits a beta of 0.48, which indicates that the share price is significantly less volatile than the broader market, moving with roughly half the magnitude of market swings and offering a defensive characteristic often sought in healthcare utility-like assets.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of -0.1% year-over-year and an earnings growth rate of -9.1% year-over-year. The divergence between these figures, where earnings are contracting at a much faster rate than revenue, implies that cost pressures or specific segment underperformance are impacting the bottom line more severely than top-line sales volumes currently. Regarding income generation, the company offers a dividend yield of 0.6% with a payout ratio of 12.0%, indicating a highly conservative approach to dividend distribution that is easily sustainable given the current earnings base. This low payout ratio allows the company to retain the vast majority of its earnings to reinvest in the business, potentially expanding its physician network or upgrading facilities, rather than prioritizing high dividend growth. The overall growth and income profile presents a scenario of a mature, low-volatility business that prioritizes capital efficiency and dividend sustainability over aggressive expansion or significant earnings acceleration in the short term.